Cancer Epidemiol Biomarkers Prev by Ioannidis, John P.A. et al.
Knowledge Integration in Cancer: Current Landscape and Future 
Prospects
John P.A. Ioannidis1,2, Sheri D. Schully1, Tram Kim Lam1, and Muin J. Khoury1,3
1Knowledge Integration Team, Epidemiology and Genomics Research Program, Division of 
Cancer Control and Population Sciences, NCI, NIH
2Stanford Prevention Research Center, Department of Medicine and Department of Health 
Research and Policy, Stanford University School of Medicine, and Department of Statistics, 
Stanford University School of Humanities and Sciences, Stanford, California
3Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia
Abstract
Knowledge integration includes knowledge management, synthesis, and translation processes. It 
aims to maximize the use of collected scientific information and accelerate translation of 
discoveries into individual and population health benefits. Accumulated evidence in cancer 
epidemiology constitutes a large share of the 2.7 million articles on cancer in PubMed. We 
examine the landscape of knowledge integration in cancer epidemiology. Past approaches have 
mostly used retrospective efforts of knowledge management and traditional systematic reviews 
and meta-analyses. Systematic searches identify 2,332 meta-analyses, about half of which are on 
genetics and epigenetics. Meta-analyses represent 1:89-1:1162 of published articles in various 
cancer subfields. Recently, there are more collaborative meta-analyses with individual-level data, 
including those with prospective collection of measurements [e.g., genotypes in genome-wide 
association studies (GWAS)]; this may help increase the reliability of inferences in the field. 
However, most meta-analyses are still done retrospectively with published information. There is 
also a flurry of candidate gene meta-analyses with spuriously prevalent "positive" results. 
Prospective design of large research agendas, registration of datasets, and public availability of 
data and analyses may improve our ability to identify knowledge gaps, maximize and accelerate 
translational progress or—at a minimum—recognize dead ends in a more timely fashion.
Introduction
Given the rapid expansion of scientific information, there is a critical need to ensure that 
maximal use is made of the collected data in a most efficient and unbiased way. "Knowledge 
integration" describes the processes that aim at effective use of information from many 
sources for accelerating translation of scientific discoveries into clinical applications, 
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evidence-based recommendations, use in practice, and eventually health benefits for 
individuals and populations (Fig. 1). The term has been used with different definitions and 
perspectives (1–3), but here we adopt the definition that includes knowledge management 
(KM), knowledge synthesis (KS), and knowledge translation (KT; ref. 1). These 3 processes 
can inform the continuum of translational research from discovery to population health 
impact (1). The knowledge integration engine can drive research progress, especially in 
data-intensive fields.
Previously, knowledge integration has depended mostly on retrospective efforts of horizon 
scanning, traditional systematic reviews and meta-analyses, and nonsystematic knowledge 
brokering between stakeholders. These efforts may be inadequate in the current era of rapid 
accumulation of multilevel information—from molecular to the macro-level of 
environmental exposures and health system attributes. Revamping the current knowledge 
integration processes may help drive the future of cancer epidemiology across the 
translational research continuum. Here, we overview the accumulated experience on 
knowledge integration with emphasis on cancer epidemiology. We discuss what methods 
have been used over time, their strengths and limitations, and what alternative approaches 
might lead to more efficient integration of emerging information.
Published information on cancer
PubMed (search August 27, 2012) lists 2,673,926 articles with the search on "cancer," of 
which more than three quarters (n = 2,146,156) are tagged with "human." Table 1 shows 
selective subsets that present an overall picture of published evidence for different types of 
designs relating to cancer epidemiology. More than 50,000 articles are identified with the 
search word "cohort," and slightly more with "case control," whereas the term "risk" 
retrieves more than 200,000 articles, and "biomarker" just as many. At the same time, there 
are also more than 100,000 clinical trial publications, many of which are randomized trials. 
Efforts to synthesize this information are represented by more than 6,000 meta-analyses, 
almost 30,000 systematic reviews, and more than 300,000 nonsystematic reviews. Thus, 
most efforts at evidence integration still use subjective opinion and nonsystematic methods 
for data overview and interpretation.
It is difficult to accurately separate the literature on associations from the literature on 
treatments and interventions—sometimes they intermingled in the same article. Subsets 
searches in Table 1 should be reviewed with caution given the non-perfect sensitivity and 
specificity of PubMed searches. However, clearly articles with relevance to treatment far 
outnumber articles with relevance to prevention across all subsets. Table 1 also provides 
search results with the string "NOT (trial* OR treatment)" to further exclude articles on 
clinical trials and treatmentrelated research (which can be either randomized or 
observational, e.g., predictive tools for treatment response). As shown, studies with "cohort" 
or "case control" are split between the literature with and without trials/treatment 
implications.
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Knowledge management: studies, data, analyses
KM efforts can take many different forms, depending on whether one is tapping into 
published information; retrieving unpublished information; developing databases with raw 
data; or allowing a live stream of all collected data and analyses (Table 2). Published 
information is only a fraction of the total raw data that have been collected for or repurposed 
for research purposes and of the analyses that have been formally conducted, probed, or 
contemplated (4).
Efforts of KM for published data concentrate usually at search optimization, curation, 
cleaning, and harmonization. Published data may often be a selected, even distorted, subset 
of the whole information chosen based on statistical significance and/or other selection 
filters (5). Although some journals have begun efforts to publish "null" results (6, 7), these 
remain underrepresented in the published literature. If so, KM targeting past published data 
may yield largely misleading results. Empirical meta-research evaluations on the credibility 
of research findings in different research fields and with different methods and technologies 
may help anchor some credibility estimates. They may help decide whether a field is 
severely biased that it is a wasteful effort to collect, clean, and use published information. 
Conversely, the KM process may indicate that a systematic synthesis can indeed yield 
reliable results.
Unpublished data and analyses results are notoriously difficult to unearth. Some 
investigators may claim that unpublished data can be ignored, as they have not passed peer 
review. However, the seal of peer review is not a perfect discriminant. Registration of 
protocols and analyses would have helped to understand the depth of the problem. 
Nevertheless, publication of these documents is limited. For example, it is well documented 
that many clinical trials protocols and/or analyses are never published. Of those that are 
published, half or more of the originally considered outcomes are not reported, whereas 
many others are reported with analyses and results that deviate from the originally intended 
analyses (8–10). For observational epidemiology, these problems are probably more 
common (11). However, a priori registration of protocols is difficult for such studies, given 
their exploratory and iterative nature. Instead, it has been argued that registration should 
focus on study datasets (4, 12), that is, information on what variables have been collected 
and measured. This allows an understanding and assessment how many registered datasets 
could have undergone specific analyses.
Public deposition of raw datasets has attracted increasing attention over time, with several 
successful efforts for laboratory research, for example, genomic sequencing databases and 
functional databases (13). For microarray, macromolecular, and protein data, most high-
impact journals have policies that require delineating some plan of making raw data, 
protocols, and analysis codes publicly available, routinely or after request to the authors; 
public deposition of such information is often a prerequisite for publication, but these 
policies are not necessarily enforced (14, 15).
There are several challenges related to deposition of raw datasets (Table 2). Some datasets 
may be deposited with poor documentation that hinders their usage by an outsider or may 
lead to erroneous data readings and misleading inferences. In addition, some public 
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databases have minimum requirements when depositing data. Even if investigators are 
required to adhere to data-sharing policies (either from funding agencies or journal 
requirements), they often enter the minimal amount of required information. There are 
different modes of data access: open-to-all, cursory approval–based, and access to select 
investigators passing stringent standards of recognized expertise. Striking a balance between 
credit and independence is also challenging. Original investigators could (or should) be 
credited for analyses conducted on their data. However, it may also be advisable to keep 
further analyses separate from them: subsequent investigators who then use these published 
data should feel free to repeat and challenge the original analyses.
Finally, the live stream information model suggests that data, protocols, and analyses are 
readily available and visible to a wider circle, even the full public, as they accumulate, 
change, and evolve. This practice has been piloted in experiments trying to replicate the 
finding of bacteria with arsenic-containing DNA (16). Other fields, including cancer 
epidemiology, may also learn from it.
Knowledge synthesis of same-level information
There is a wide variety of KS methods (Table 2), but systematic reviews and meta-analyses 
are the most common. The majority of such reviews still depend on published information. 
Meta-analyses of published data are popular in many disciplines, especially those where 
unadjusted estimates and plain 2 × 2 tables are convenient. Some efforts may also be made 
to retrieve and include unpublished information, but success in this endeavor varies. For 
fields where there are many meta-analyses, field synopses have emerged (17) with 
simultaneous compilation of tens to millions of meta-analyses on the same field, as in 
several examples of applications in human genome epidemiology, for example, AlzGene, 
SzGene, and PDGene (18–20).
Other KS efforts involve investigators who control existing primary data. Such collaborative 
meta-analyses use a central secretariat to collect, query, clean, and synthesize individual-
level data or statistics derived from individual-level data analyses procured by the original 
investigators of each included study. The advantages (potential standardization or 
harmonization of data and analyses, consistency of adjustments, multivariable models, 
interactions, and other complex models) and disadvantages (cost, effort, inability to fully 
standardize post hoc, selective availability of information, political difficulties) of this 
approach versus meta-analyses of the published literature have been extensively discussed 
previously (21, 22).
There is increasing interest in collaborative meta-analyses that use prospectively collected 
measurements from existing studies. This is the dominant paradigm in meta-analyses of 
GWAS (23, 24) that have led to a massive increase in the number of discovered genetic 
variants with strong statistical support (25). These meta-analyses may avoid the potential for 
selective reporting bias that threatens collaborative meta-analyses of previously collected 
data. Consortia working in this framework are common in human genome epidemiology but 
less common in other fields. Finally, one can envision prospective meta-analyses, where not 
only specific measurements but also the primary studies are designed prospectively, with the 
plan to eventually combine them. Such examples currently exist mostly from randomized 
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trials (26). Nevertheless, the concept can conceivably be applied to future designed case–
control studies, cohort studies, and biobanks (27), with prospective standardization of their 
designs and data collection and analyses procedures (28).
Landscape of KS methods used in cancer epidemiology
Table 3 shows the landscape of practiced KS methods for the PubMed subset of "Cancer 
NOT (trial* OR treatment)". The large majority of systematic reviews (85.5%) and all but 
13 meta-analyses addressed human data. More effort is needed to systematically appraise 
evidence from animal studies (29, 30), which can be informative and influential for judging 
biologic plausibility and for other preclinical inferences.
The fields of genetics or epigenetics dominate almost a third of the literature. 
Correspondingly, the same distribution applies to systematic reviews, whereas these 2 
disciplines account for about half of the existing meta-analyses. The literatures on 
biomarkers, hormones, and infectious agents are extensive but have relatively fewer meta-
analyses (n = 51–109 in each). Conversely, other concentrations with smaller shares of the 
total literature instead have as many or more published meta-analyses, in particular smoking, 
occupational, and nutritional fields.
The number of systematic reviews is 2- to 3-fold larger than the number of meta-analyses in 
most areas, except for biomarkers, immune/allergy/asthma, and social/socioeconomic 
factors, where the ratio is even larger. This may reflect the difficulty of conducting 
quantitative syntheses (e.g., for social and socioeconomic factors with extreme heterogeneity 
of definitions and measurements) or less established traditions for conducting meta-analyses. 
The ratio of all published articles per published meta-analysis is 556 overall; despite their 
emerging popularity, metaanalyses are still a small portion of the literature. Moreover, there 
is large variability in this ratio across different fields. It is smaller [n (all)/n (MA) = 89–133] 
for smoking, occupational, nutritional, and lifestyle areas; modestly high [n (all)/n (MA) = 
215–350] for alcohol, social, genetics, carcinogens, and radiation; and very high [n (all)/n 
(MA) = 728–1,162] in epigenetics, biomarkers, immune factors, hormones, and infectious 
agents.
A more detailed examination of a sample of meta-analyses published in 1992, 2002, and 
2012 shows the evolution of the application of these methods over time. "Cancer NOT 
(trial* OR treatment) AND meta-analysis [type]" yields 25 items in 1992, 49 in 2002, and 
232 in the first 8 months of 2012 alone. On closer examination, 20 of the 25 meta-analysis–
tagged articles published in 1992 are indeed meta-analyses related to cancer epidemiology, 
and the same applies to 44 of 49 tagged articles in 2002 and 50 of the 53 latest indexed 
articles in 2012.
Besides the geometric increase in the number of published meta-analysis articles each year, 
the areas represented have changed over time. The advent of metaanalyses on genetics and 
epigenetics is impressive. In 1992, there was only one quantitative review on leukemia 
cytogenetics. In 2002, of the 44 meta-analyses, 8 (18%) assessed genetic variants, 1 (2%) 
genomic hybridization, and 1 (2%) microarrays. In 2012, of the 50 most recently indexed 
published meta-analyses, 25 (50%) were on genetic variants, 2 (4%) on epigenetics, and 
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another one on gene–menopause interaction. No other field in 2012 had such staggering 
increase in the number of meta-analyses (smoking, n = 3; alcohol, n = 3; biomarkers, n = 2; 
infectious agents, n = 2; dietary, n = 2; social, n = 1; occupational, n = 1; diagnostic tests, n 
= 3, other, n = 3 among 50 meta-analyses examined).
Moreover, there have been an increasing number of genes and genetic variants examined in 
meta-analyses over time. All genetic meta-analyses in 2002 focused on specific genes. 
Conversely, meta-analyses in 2012 included also genome-wide association meta-analyses, 
consortium analyses examining a number of variants, and field synopses. There is also a 
discernible change in the types of meta-analyses conducted over time, in particular about the 
use of consortium approaches and use of individual-level data (31). In the examined 
samples, there were 2 meta-analyses using individual-level data in 1992 (among 20), 5 in 
2002 (among 44), and 9 among the most recent 50 meta-analyses in 2012. All the meta-
analyses with individual-level data in 1992 and 2002 combined information that had been 
already collected in existing studies. One meta-analysis combined data from publicly 
available data on microarray experiments, whereas all the other meta-analyses created 
collaborative structures where investigators contributed their data and participated in the 
final manuscripts. These analyses pertained to nutritional factors (n = 4), hormones (n = 1), 
or smoking and alcohol (n = 1). Conversely, in 2012, the 9 meta-analyses using individual-
level data targeted a very different set of risk factors: genetic factors (n = 6), gene expression 
data (n = 1), biomarkers (n = 1) and endometriosis (n = 1). The 6 meta-analyses of genetic 
factors were done by consortia conducting with genotype data generated prospectively for 
the project. The gene expression meta-analysis used data from publicly available databases, 
and the other 2 meta-analyses were done by investigators contributing previously collected 
data.
Caveats in current meta-analyses in cancer epidemiology
Despite the increase in the number and proportion of meta-analyses with individual-level 
data over time, these still represent the minority. Most currently published metaanalyses in 
cancer epidemiology continue to depend on published summary data. Many of these meta-
analyses focus on genetic variants, often targeting a single or a few candidate genes and 
variants thereof. Interestingly, among the 50 published meta-analyses from 2012, 12 were 
done in China focusing on specific candidate genes from the era preceding GWAS. With 
one exception (32), all of these Chinese meta-analyses concluded that the examined 
candidate genes are significantly associated with the phenotypes of interest, although the P 
values were always very modest. On the basis of previous experience on candidate gene 
associations (33, 34), the credibility of these associations is very low. Another 3 meta-
analyses from China addressed genetic variants previously highlighted from GWAS and also 
included primary data that the authors generated in their own sample and claimed replication 
of the genetic effects. Including also other fields beyond genetics, overall, 19 of the 50 
(38%) meta-analyses in 2012 were from China and 17 of these 19 concluded with 
significant, favorable results. Previous empirical evaluations suggest that studies from China 
in different fields have frequent or even ubiquitous "positive" findings (35, 36).
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The very high prevalence of "positive" meta-analyses, at the face of what should be mostly 
null associations, is worrisome. Apparently automation has allowed the massive production 
of potentially unreliable meta-analyses. The problem seems to be most acute for genetic 
epidemiology, which carries a lion’s share in currently published meta-analyses, but may 
extend also in other disciplines.
Knowledge synthesis: multiple-level information
Besides KS involving the same type of information combined across different studies, KS 
may also try to synthesize multiple levels of information and/or simulated rather than real 
data. Cross-design synthesis approaches can combine data from different types of designs 
and umbrella reviews try to compile information on different aspects of questions of interest, 
for example, incidence, prevalence, associations, predictive performance, and clinical 
treatment effects, if pertinent (37). The IARC monographs combine basic and epidemiologic 
data to arrive at a systematic approach to classification of carcinogens (38). The HuGENet 
Venice criteria attempt to do this for genetic associations (39) and Boffetta and colleagues 
recently proposed a merging of IARC monograph and Venice methods appraising evidence 
on gene–environment interactions (40).
As knowledge progresses from discovery to health-related applications, mixed methods 
become increasingly used to examine the evidence of validity and use of the information. 
Examples of KS using a mixture of methods for more advanced translation steps include the 
US Preventive Services Task Force documents for clinical preventive services (41) such as 
prostate and breast cancer screening (T2 translation stage, "does it work"), the CDC 
Community Guide for Preventive Services (ref. 42; T3 translation stage, "how does it work 
in community settings"), and CISNet, an NCI-funded consortia that evaluate using modeling 
and empirical data the impact of different interventions on real-world population outcomes 
(T4 translation stage), for example, as in a recent modeling article on contribution of 
screening and survival differences to racial disparities in colorectal cancer rates (43).
Knowledge synthesis: meta-research
Meta-research (research on research) may allow obtaining wide views on evidence 
concerning multiple research questions across one or more fields. It may help understand 
general patterns of study design, reporting, and biases. For example, meta-research 
evaluations have documented the problems of selective reporting and excess significance 
biases in cancer epidemiology studies and their meta-analyses (44–50). One may list here 
also efforts to reproduce published results. Such efforts, ranging from "forensic 
bioinformatics" to "reproducibility checks," have shown major reproducibility problems in 
several research fields such as -omics signatures (51) or preclinical data on drug targets (52).
Knowledge translation: using science to influence research, policy, and practice
KM and KS are not sufficient to move promising applications and interventions into 
practice. KT is a proactive process that involves communicating and disseminating 
synthesized information to influence policy, guideline development, practice, and research 
across the translation continuum. This is the most "messy" component of knowledge 
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integration; it requires the "buy-in" from stakeholders with different perspectives, for 
example, see the recently discussed dissemination and implementation agenda for NIH (53).
Many forces affect the diffusion, adoption, and implementation of evidence-based 
recommendations into policy and practice and often operate independently from KS. They 
include public and private investments in research and development, policy and legal 
frameworks, oversight and regulation, product marketing, coverage and reimbursements, 
consumer advocacy, provider awareness, access, and health care services development and 
implementation. Deverka and colleagues (54) showed that for cancer genomic applications, 
different stakeholders hold disparate views of the synthesized knowledge presented to them. 
For example, payers generally require a higher level of evidence of clinical use than 
genomic researchers or test developers. Issues around differential access and implementation 
may contribute to the "lost in translation" phenomenon (55).
One aspect of KT may involve convening stakeholders around KS to address differences in 
evidentiary thresholds that drive decision making. This convening function of "knowledge 
brokering" links researchers and policy makers to facilitate interactions and forge 
partnerships to use evidence from existing knowledge and define areas for future research. 
In fields with rapidly changing landscape such as cancer genomics, KT knowledge 
brokering may need more robust proactive stakeholder engagement earlier in the decision-
making process rather than later (1).
Conclusions and future prospects
The landscape of knowledge integration in cancer epidemiology has changed substantially 
over time and it continues to change. New methods are used more widely for managing, 
synthesizing, and translating information. Table 4 summarizes some possibilities that may 
enhance knowledge integration efforts in the future.
KM may benefit from more proactive steps rather than waiting to handle selectively 
reported, fragmented published data. Registration of observational datasets (4, 56), more 
systematic availability of raw data and analysis codes (57, 58), facilitation of repeatability 
and reproducibility checks (59), building a replication culture (60), and even consideration 
of live streaming of information may accelerate science, allow prompt recognition of false 
positives and dead ends, and facilitate translation of interesting observations that can be 
repeated and validated. The optimal way and implementation mode to achieve these changes 
needs carefully study.
In KS, the paradigm of large-scale international collaboration with prospective data 
collection has become dominant in human genome epidemiology (29), but it can also 
permeate more broadly many other fields. New epidemiologic studies and biobanks (25) 
may also be designed with the outlook that they will form part of a larger prospective 
network, rather than isolated proprietary experiments. For many diseases and subfields, it is 
possible that their several consortia with overlapping purposes may continue to co-exist. 
This may not necessarily be a drawback, as this may promote competition and independent 
replication across consortia. Regardless, it is important to have wide views of the 
information that is or could become available. This would help avoiding having to fund yet 
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another study when there are hundreds available that can easily address the same question 
(4) or to prioritize studies and data collection in fields where the wider map of global 
evidence seems to have a dearth of data.
Finally, KT could benefit by wider spread and brokering of sound evidence from more 
reliable KM and KS efforts. It may be easier to set upfront goals, expectations, and rules of 
engagement and make all stakeholders aware of them, rather than wait for debates to be 
settled post hoc. A fascinating aspect of science is that not everything can be anticipated, but 
this does not mean that we cannot try to have some upfront planning and more transparency 
in protocols, analysis plans, and results.
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Table 1
Published articles in cancer literature
PubMed Treatment Prevention Not (trial or treatment)
Cancer 2,673,926 1,360,697 208,187 1,295,958
+Animal 481,080 206,009 40,891 269,653
+Cell 1,118,600 510,286 66,935 604,187
+Cohort 53,567 29,808 8,683 22,819
+Case–control 59,248 11,255 5,848 26,973
+Risk 267,490 158,529 58,002 105,276
+Biomarker 204,419 91,298 15,675 111,025
+Clinical trial, type 105,939 93,172 14,807 4,535
+RCT, type 34,449 31,862 8,047 0
+Meta-analysis, type 6,406 3,902 1,153 2,332
+Systematic review, type 28,922 21,398 5,755 6,763
+Review, type 314,176 201,162 39,859 111,234
NOTE: Search strategies: treatment: "treatment", prevention: "prevention OR screening [ti] OR screening [tw]", Not trial or treatment: "NOT 
(trial* OR treatment)."
Abbreviation: RCT, randomized controlled trial.
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Table 2
Different approaches to KM and KS
Knowledge management
 Published data: optimization of search engines, curation
  and cleaning, harmonization
 Unpublished data: detection, registration, cleaning
 Deposition of raw datasets in public: documentation,
  access control, ease of use, credit, independence
 Live stream information
Knowledge synthesis
  Same-level of information
  Systematic reviews of published information
  Meta-analyses of published information
  Meta-analyses including also retrieved unpublished
   data
  Field synopses of many meta-analyses
  Collaborative meta-analyses of previously collected
   individual-level data
  Collaborative meta-analyses of prospectively collected data from
   existing studies
  Prospective consortia and meta-analyses thereof
  Multiple levels of information
  Cross-design synthesis and multilevel evidence
   appraisals
  Modeling with real or simulated data
  Meta-research (research on research)
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Table 3
Systematic reviews and meta-analyses in different fields of cancer (excluding trials and treatment)
Search terms All articles, N (all) n (SR) n (MA) n (SR)/n (MA) n (all)/n (MA)
Gene/genome/genetic 268,597 1,999 920 2.2 291
Epigenetic/methylation/mutation 115,763 497 159 3.1 728
Immune/allergy/asthma 29,046 107 25 4.3 1162
Hormone 53,679 148 51 2.9 1,032
Social/socioeconomic 11,531 224 50 4.5 231
Diet/dietary/nutrition/nutritional 19,549 289 147 2.0 133
Physical activity/exercise/obesity 8,919 192 74 2.6 121
Virus/bacteria/infection/infectious 88,881 331 109 3.0 815
Carcinogen 30,286 201 88 2.3 344
Radiation 30,124 229 86 2.6 350
Occupation/occupational 16,839 344 177 1.9 95
Smoking/smoke/tobacco 20,660 413 232 1.8 89
Alcohol 17,921 170 83 2.0 215
Biomarker 72,709 373 97 3.8 750
NOTE: On the basis of PubMed searches conducted on August 29, 2012. The search resulted in 1,295,958 items overall, of which 6,763 were 
tagged by PubMed as systematic reviews and 2,332 as meta-analyses; when limited to studies tagged as human, there were 941,360 items overall, 
5,780 systematic reviews, and 2,319 meta-analyses. All searches use as a backbone the search strategy "Cancer NOT (trial* OR treatment)" so as to 
avoid capturing articles on clinical trials and treatments. Some articles from case-control and cohort studies where treatment or treatment-related 
questions are discussed would be excluded by this strategy, but this latter group accounts generally for few meta-analysis, for example, a search 
with "Cancer AND (trial* OR treatment) AND (case-control or cohort) AND meta-analysis [type]" yields an additional 451 items (besides the 
2,332 identified with "Cancer NOT (trial* OR treatment) AND meta-analysis [type]"); in a sample of 20 of the 451, only 10 are related to cancer 
epidemiology. Conversely, in detailed scrutiny of a sample of 127 items, among those identified with the search "Cancer NOT (trial* OR 
treatment) AND meta-analysis [type]", 114 are indeed meta-analyses of cancer epidemiology topics (positive predictive value 90%). Thus, the 
provided estimate of 2,332 metaanalysis articles in cancer epidemiology seems to be quite accurate, with <250 falsely identified articles and 
roughly equal number of falsely nonidentified articles. All searches in the table, with the exception of Gene/Genome/Genetic and Epigenetic/
Methylation/Mutation, use the string "NOT (Gene OR Genome OR Genetic)", so as to exclude items that deal primarily with genetics, for example, 
immune response genes or hormone-related genes.
Abbreviations: N (all), total number of articles retrieved; n (SR), number of articles retrieved with type: systematic review; n (MA), number of 
articles retrieved with type: meta-analysis.
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Table 4
Suggestions for the future of knowledge integration
Knowledge management
 Methods for mining published and unpublished data
 Registration of observational datasets and, when
  appropriate, protocols
 Availability of raw data and analysis codes
 Facilitation of repeatability and reproducibility checks,
  replication culture
 Consideration of live stream information
Knowledge synthesis
 Facilitation of consortia with prospective measurements
 Optimization of multiconsortial space, competition, and
  communication
 Prospective study networks
Knowledge translation
 Anticipatory rather than post hoc brokering
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